The recommendations, published June 18 in JAMA, replace the task force’s 2017 guidance that recommended providers screen children for obesity. The task force considers the guidance a B recommendation, indicating a high degree of certainty of moderate benefits and requiring most private health insurance plans to cover treatment without a copay.
The updated recommendations do not include prescribing GLP-1 drugs.
